Tara L. Frenkl

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni et al. · The Lancet Oncology · 2021 · 513 citations

Urology, Surgical Oncology, Genitourinary Cancer +7

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Yves Fradet, Joaquim Bellmunt, David J. Vaughn et al. · Annals of Oncology · 2019 · 473 citations · Full text

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano et al. · Journal of Clinical Oncology · 2020 · 283 citations · Full text

Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).

Arjun Vasant Balar, Girish S. Kulkarni, Edward Uchio et al. · Journal of Clinical Oncology · 2019 · 113 citations

Urology, Phase Ii Trial, Genitourinary Cancer +13

Discovery of Vibegron: A Potent and Selective β₃Adrenergic Receptor Agonist for the Treatment of Overactive Bladder

Scott D. Edmondson, Cheng Zhu, Nam Fung Kar et al. · Journal of Medicinal Chemistry · 2015 · 101 citations · Full text